Edition:
India

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.68USD
10:12pm IST
Change (% chg)

$-0.02 (-1.18%)
Prev Close
$1.70
Open
$1.70
Day's High
$1.72
Day's Low
$1.68
Volume
9,897
Avg. Vol
84,661
52-wk High
$3.74
52-wk Low
$0.71

Select another date:

Mon, Dec 4 2017

BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA

* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [http://bit.ly/2jcVpeo] Further company coverage:

BRIEF-Moleculin Biotech Q3 loss per share $0.14‍​

* Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017

BRIEF-Moleculin appoints Sandra Silberman as chief medical officer

* Moleculin appoints Dr. Sandra Silberman as chief medical officer -- new products Source text for Eikon: Further company coverage:

BRIEF-Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

* Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

BRIEF-Moleculin requests for clinical trial authorization to study annamycin

* Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland Source text for Eikon: Further company coverage:

BRIEF-Moleculin announces strategic collaboration to develop immune stimulation drug

* Moleculin announces strategic collaboration to develop immune stimulation drug

BRIEF-Moleculin announces FDA approval of Annamycin IND

* Moleculin Biotech - ‍U.S. IND allows Moleculin to make submission to Polish authorities for planned Annamycin clinical trial to be conducted in Poland​ Source text for Eikon: Further company coverage:

BRIEF-Moleculin engages CRO to begin clinical trials of WP1220 for the treatment of cutaneous T-Cell lymphoma

* Moleculin engages CRO to begin clinical trials of WP1220 for the treatment of cutaneous T-Cell lymphoma

BRIEF-Moleculin to combine brain cancer drug candidate with Roche's Avastin

* Moleculin to collaborate on combining its WP1122 brain cancer drug candidate with Roche's drug Avastin

BRIEF-Moleculin announces filing with FDA of IND for its leukemia drug Annamycin

* Moleculin announces filing with FDA of IND for its leukemia drug Annamycin

Select another date: